Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Blood neutrophil counts in HIV-infected patients with cryptococcal meningitis: Association with mortality.

Musubire AK, Meya DB, Rhein J, Meintjes G, Bohjanen PR, Nuwagira E, Muzoora C, Boulware DR, Hullsiek KH; COAT and ASTRO trial teams.

PLoS One. 2018 Dec 31;13(12):e0209337. doi: 10.1371/journal.pone.0209337. eCollection 2018.

2.

Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis.

Boulware DR, Meya DB, Muzoora C, Rolfes MA, Huppler Hullsiek K, Musubire A, Taseera K, Nabeta HW, Schutz C, Williams DA, Rajasingham R, Rhein J, Thienemann F, Lo MW, Nielsen K, Bergemann TL, Kambugu A, Manabe YC, Janoff EN, Bohjanen PR, Meintjes G; COAT Trial Team.

N Engl J Med. 2014 Jun 26;370(26):2487-98. doi: 10.1056/NEJMoa1312884.

3.

Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda.

Liechty CA, Solberg P, Were W, Ekwaru JP, Ransom RL, Weidle PJ, Downing R, Coutinho A, Mermin J.

Trop Med Int Health. 2007 Aug;12(8):929-35.

4.

Prognostic implications of baseline anaemia and changes in haemoglobin concentrations with amphotericin B therapy for cryptococcal meningitis.

Tugume L, Morawski BM, Abassi M, Bahr NC, Kiggundu R, Nabeta HW, Hullsiek KH, Taseera K, Musubire AK, Schutz C, Muzoora C, Williams DA, Rolfes MA, Meintjes G, Rhein J, Meya DB, Boulware DR.

HIV Med. 2017 Jan;18(1):13-20. doi: 10.1111/hiv.12387. Epub 2016 Apr 28.

5.

Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes.

Jarvis JN, Bicanic T, Loyse A, Namarika D, Jackson A, Nussbaum JC, Longley N, Muzoora C, Phulusa J, Taseera K, Kanyembe C, Wilson D, Hosseinipour MC, Brouwer AE, Limmathurotsakul D, White N, van der Horst C, Wood R, Meintjes G, Bradley J, Jaffar S, Harrison T.

Clin Infect Dis. 2014 Mar;58(5):736-45. doi: 10.1093/cid/cit794. Epub 2013 Dec 6.

6.

Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa.

Makadzange AT, Ndhlovu CE, Takarinda K, Reid M, Kurangwa M, Gona P, Hakim JG.

Clin Infect Dis. 2010 Jun 1;50(11):1532-8. doi: 10.1086/652652.

PMID:
20415574
7.

Survival time of HIV-infected patients with cryptococcal meningitis.

Chottanapund S, Singhasivanon P, Kaewkungwal J, Chamroonswasdi K, Manosuthi W.

J Med Assoc Thai. 2007 Oct;90(10):2104-11.

PMID:
18041430
8.

Blood neutrophil counts in HIV-infected patients with pulmonary tuberculosis: association with sputum mycobacterial load.

Kerkhoff AD, Wood R, Lowe DM, Vogt M, Lawn SD.

PLoS One. 2013 Jul 9;8(7):e67956. doi: 10.1371/journal.pone.0067956. Print 2013.

9.

Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa.

Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, Harrison TS.

Clin Infect Dis. 2009 Apr 1;48(7):856-62. doi: 10.1086/597262.

10.

Long-term follow-up and survival of antiretroviral-naive patients with cryptococcal meningitis in the pre-antiretroviral therapy era, Gauteng Province, South Africa.

Park BJ, Shetty S, Ahlquist A, Greenbaum A, Miller JL, Motsi A, McCarthy K, Govender N; Gauteng Cryptococcal Surveillance Initiative Group.

Int J STD AIDS. 2011 Apr;22(4):199-203. doi: 10.1258/ijsa.2010.010235.

PMID:
21515751
11.

No association of cryptococcal antigenemia with poor outcomes among antiretroviral therapy-experienced HIV-infected patients in Addis Ababa, Ethiopia.

Smitson CC, Tenna A, Tsegaye M, Alemu AS, Fekade D, Aseffa A, Blumberg HM, Kempker RR.

PLoS One. 2014 Jan 21;9(1):e85698. doi: 10.1371/journal.pone.0085698. eCollection 2014.

12.

Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis.

Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, Denning DW, Loyse A, Boulware DR.

Lancet Infect Dis. 2017 Aug;17(8):873-881. doi: 10.1016/S1473-3099(17)30243-8. Epub 2017 May 5.

13.

A Glucuronoxylomannan-Associated Immune Signature, Characterized by Monocyte Deactivation and an Increased Interleukin 10 Level, Is a Predictor of Death in Cryptococcal Meningitis.

Scriven JE, Graham LM, Schutz C, Scriba TJ, Wilkinson KA, Wilkinson RJ, Boulware DR, Urban BC, Lalloo DG, Meintjes G.

J Infect Dis. 2016 Jun 1;213(11):1725-34. doi: 10.1093/infdis/jiw007. Epub 2016 Jan 14.

14.

Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial.

Mfinanga S, Chanda D, Kivuyo SL, Guinness L, Bottomley C, Simms V, Chijoka C, Masasi A, Kimaro G, Ngowi B, Kahwa A, Mwaba P, Harrison TS, Egwaga S, Jaffar S; REMSTART trial team.

Lancet. 2015 May 30;385(9983):2173-82. doi: 10.1016/S0140-6736(15)60164-7. Epub 2015 Mar 10.

PMID:
25765698
15.

Implementation and operational research: Integrated pre-antiretroviral therapy screening and treatment for tuberculosis and cryptococcal antigenemia.

Pac L, Horwitz MM, Namutebi AM, Auerbach BJ, Semeere A, Namulema T, Schwarz M, Bbosa R, Muruta A, Meya DB, Manabe YC.

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):e69-76. doi: 10.1097/QAI.0000000000000527.

16.

Asymptomatic cryptococcal antigen prevalence detected by lateral flow assay in hospitalised HIV-infected patients in São Paulo, Brazil.

Vidal JE, Toniolo C, Paulino A, Colombo A, Dos Anjos Martins M, da Silva Meira C, Pereira-Chioccola VL, Figueiredo-Mello C, Barros T, Duarte J, Fonseca F, Alves Cunha M, Mendes C, Ribero T, Dos Santos Lazera M, Rajasingham R, Boulware DR.

Trop Med Int Health. 2016 Dec;21(12):1539-1544. doi: 10.1111/tmi.12790. Epub 2016 Oct 24.

17.

A retrospective study of AIDS-associated cryptomeningitis.

Sachdeva RK, Randev S, Sharma A, Wanchu A, Chakrabarti A, Singh S, Varma S.

AIDS Res Hum Retroviruses. 2012 Oct;28(10):1220-6. Epub 2012 Apr 17.

PMID:
22369456
18.

Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study.

Rhein J, Morawski BM, Hullsiek KH, Nabeta HW, Kiggundu R, Tugume L, Musubire A, Akampurira A, Smith KD, Alhadab A, Williams DA, Abassi M, Bahr NC, Velamakanni SS, Fisher J, Nielsen K, Meya DB, Boulware DR; ASTRO-CM Study Team.

Lancet Infect Dis. 2016 Jul;16(7):809-818. doi: 10.1016/S1473-3099(16)00074-8. Epub 2016 Mar 10.

19.

CLINICAL OUTCOMES OF CRYPTOCOCCAL MENINGITIS AMONG HIV-INFECTED PATIENTS IN THE ERA OF ANTIRETROVIRAL THERAPY.

Kobayashi T, Pitisuttithum P, Kaewkingwal J, Phuphuakrat A, Sungkanuparph S.

Southeast Asian J Trop Med Public Health. 2017 Jan;48(1):56-64.

PMID:
29644820
20.

Prevalence and factors associated with cryptococcal antigenemia among severely immunosuppressed HIV-infected adults in Uganda: a cross-sectional study.

Oyella J, Meya D, Bajunirwe F, Kamya MR.

J Int AIDS Soc. 2012 Mar 14;15(1):15. doi: 10.1186/1758-2652-15-15.

Supplemental Content

Support Center